716 filings
10-Q
2024 Q1
BIIB
Biogen Inc
Quarterly report
24 Apr 24
4:15pm
8-K
BIIB
Biogen Inc
24 Apr 24
First quarter revenue $2.3 billion; GAAP diluted EPS $2.70; Non-GAAP diluted EPS $3.67
7:02am
PRE 14A
BIIB
Biogen Inc
Preliminary proxy
12 Apr 24
5:01pm
10-K
2023 FY
BIIB
Biogen Inc
Annual report
13 Feb 24
5:40pm
8-K
BIIB
Biogen Inc
13 Feb 24
Biogen reports fourth quarter and full year 2023 results and expects return to Non-GAAP EPS growth in 2024
7:07am
8-K
bnvuf zarac
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:36pm
8-K
1wo g4adiomwtqq
8 Nov 23
Departure of Directors or Certain Officers
4:41pm
8-K
gtsosv1x ut
8 Nov 23
Biogen reports third quarter 2023 results and updates full year 2023 guidance
7:02am
8-K/A
n3i2gfwd mygqguf5c8w
28 Sep 23
Submission of Matters to a Vote of Security Holders
5:25pm
8-K
9am8vx z8ayid
26 Sep 23
Biogen Completes Acquisition of Reata Pharmaceuticals
5:25pm
8-K
bdz3v4i gh
1 Sep 23
Entry into a Material Definitive Agreement
4:36pm
DEFA14A
dy01yrekg3ud59at
31 Jul 23
Additional proxy soliciting materials
7:02am
8-K
pyefoa1ww45zd8q
31 Jul 23
Entry into a Material Definitive Agreement
7:00am
DEFA14A
ai54bh do8mx87o1
28 Jul 23
Additional proxy soliciting materials
7:13am
8-K
yn4u eslar
28 Jul 23
Other Events
7:11am
8-K
8v72jsq7dh38 dg33ctq
25 Jul 23
Second quarter revenue $2,456 million; GAAP diluted EPS $4.07; Non-GAAP diluted EPS $4.02
7:03am
8-K
io0h0v9mu rvh6
29 Jun 23
Submission of Matters to a Vote of Security Holders
4:24pm
DEFA14A
fptou2zgsrs8pjg
13 Jun 23
Additional proxy soliciting materials
7:28am